Insilico Medicine raises $60M to launch drug discovery robotics lab

US and Hong Kong-based startup Insilico Medicine has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors. Insilico has developed a growing portfolio in frontier areas empowered by its proprietary AI platform. Seven programmes in its internal pipeline have progressed to the IND-enabling stage, including a novel 3CL protease inhibitor for COVID-19 treatment, and two synthetic lethality programmes targeting MAT2A and USP1 for oncology. It also successfully completed a Phase 0 microdose study and entered a Phase I clinical trial with its first internally developed programme targeting fibrosis. Capital raised in the round will further bolster Insilico’s financial position and fuel the growth of its advancing pipeline, including its lead programme which is currently in a Phase I study, and continued development of its Pharma.AI platform.